FUTURE DEVELOPMENT

 

 

3D Biopsy additional applications

In addition to prostate biopsies, there are another 4.2 million biopsies performed in the United States and 18 million worldwide that could potentially be diagnosed with the 3DBiopsy system. These include organs in which precisely identifying cancer location is critical to treatment, such as the liver, kidney, and thyroid. Breast cancer is another ideal application, as it can have a similar quality-of-life impact on a woman as prostate cancer has on a man. 3DBiopsy plans to develop additional technology to expand its first prostate biopsy platform to address these other clinical opportunities.

*Investigational device. Not available for sale in the United States.

Investor Inquiries Welcome.

.

Call us at 1-800-290-6186, or email us

Brad J. Buscher
Chairman of the Board
Cell: 612-859-2551
bbuscher@3dbiopsy.com

Nelson N. Stone, MD 
President, Chief Executive Officer and Founder
Cell: 845-323-1727
nstone@3dbiopsy.com

James R. Rosa 
Vice President, Regulatory and Quality Assurance
Cell: 303-704-3374
jrosa@3dbiopsy.com

Todd J. Anderson 
Chief Financial Officer
Cell: 612-839-2457
tanderson@3dbiopsy.com

E. David Crawford, MD 
Chief Medical Advisor and Founder
Cell: 303-315-5937
dcrawford@3dbiopsy.com